Talphera’s (TLPH) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Talphera (NASDAQ:TLPH) in a research note published on Tuesday,Benzinga reports. They currently have a $6.00 target price on the stock.

TLPH has been the topic of several other research reports. Rodman & Renshaw started coverage on shares of Talphera in a report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price objective on the stock. RODMAN&RENSHAW raised shares of Talphera to a “strong-buy” rating in a report on Tuesday, January 28th.

Talphera Trading Up 7.1 %

NASDAQ TLPH opened at $0.53 on Tuesday. The firm’s fifty day simple moving average is $0.61 and its two-hundred day simple moving average is $0.71. The firm has a market capitalization of $9.03 million, a P/E ratio of -0.77 and a beta of 0.20. Talphera has a 12-month low of $0.45 and a 12-month high of $1.27.

Talphera (NASDAQ:TLPH) last announced its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.14. As a group, sell-side analysts predict that Talphera will post -0.64 earnings per share for the current fiscal year.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.